{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T02:58:13Z","timestamp":1780887493902,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002725","name":"Childhood Brain Tumor Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K01NS119351 and 1R01NS138021"],"award-info":[{"award-number":["K01NS119351 and 1R01NS138021"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","award":["\u201cA\u201d Award 23-28298"],"award-info":[{"award-number":["\u201cA\u201d Award 23-28298"]}],"id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Monka Foundation, Bella Muntean-Angel Heart of Hope Ministry"},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1 TR001451 & UL1 TR001450TL1"],"award-info":[{"award-number":["TL1 TR001451 & UL1 TR001450TL1"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006806","name":"MUSC | Hollings Cancer Center, Medical University of South Carolina","doi-asserted-by":"publisher","award":["Lowvelo"],"award-info":[{"award-number":["Lowvelo"]}],"id":[{"id":"10.13039\/100006806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006806","name":"MUSC | Hollings Cancer Center, Medical University of South Carolina","doi-asserted-by":"publisher","award":["Lowvelo Fellowship"],"award-info":[{"award-number":["Lowvelo Fellowship"]}],"id":[{"id":"10.13039\/100006806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011482","name":"MUSC | Department of Urology, Medical University of South Carolina","doi-asserted-by":"publisher","award":["Odyssey Fellowship"],"award-info":[{"award-number":["Odyssey Fellowship"]}],"id":[{"id":"10.13039\/100011482","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R00 CA241367"],"award-info":[{"award-number":["R00 CA241367"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    While outcomes for most children with medulloblastoma (MB) are relatively favorable, those in the Sonic Hedgehog (SHH) subgroup with\n                    <jats:italic>Tumor protein P53<\/jats:italic>\n                    (\n                    <jats:italic>TP53<\/jats:italic>\n                    ) mutations\u2014known as the SHH\u03b1 subtype\u2014face a much poorer prognosis. SHH\u03b1 patients relapse more frequently and rapidly, underscoring the need for therapies that prevent recurrence. We recently identified a non-canonical Gli-driven Sox2\u207a cell population that promotes relapse in SHH MB. However, few Gli-targeting strategies have shown clinical promise to date. One translational Gli inhibitor is pyrvinium, an FDA-approved compound known to destabilize Gli through increasing Casein kinase 1\u03b1 (CK1\u03b1) activity. In this study, we tested whether pyrvinium and a brain-permeable derivative, SSTC3, affect stemness and relapse risk in mouse and human-derived SHH\u03b1 MB models. We found that pyrvinium suppresses the Gli-driven proliferation of Sox2\u207a cells. Unlike other SHH\/Gli-targeting approaches, pyrvinium also impaired MB self-renewal by depleting Cluster of Differentiation 15 (CD15)\u207a cells. Mechanistic studies revealed that CD15\u207a cell self-renewal is WNT-dependent and driven by the loss of p53\/\n                    <jats:italic>microRNA-34a<\/jats:italic>\n                    -mediated repression of WNT signaling. Remarkably, pyrvinium and SSTC3 reduced Sox2\u207a, CD15\u207a, and dual Sox2\/CD15-labeled populations in mouse and patient-derived SHH\u03b1 models. Consistent with their ability to diminish tumor stemness, pyrvinium also impaired primary and secondary tumor engraftment. Our findings show that CK1\u03b1 agonists regulate stemness in SHH\u03b1 MB, establishing CK1\u03b1 as a therapeutically relevant vulnerability. While pyrvinium itself is not an ideal clinical candidate, these data support the development of second-generation brain-penetrant CK1\u03b1-targeting derivatives.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08762-6","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:47:32Z","timestamp":1777020452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CK1\u03b1 agonists attenuate medulloblastoma stemness and relapse risk"],"prefix":"10.1038","volume":"17","author":[{"given":"Kendell","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Turos-Cabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritika","family":"Shahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April D.","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Swiderska-Syn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia D. S.","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Alfaro-Quinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Kliebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley J.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Palomo-Caturla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis L.","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5588-6281","authenticated-orcid":false,"given":"Thibaut","family":"Barnoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1839-6181","authenticated-orcid":false,"given":"Jezabel","family":"Rodriguez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"6","key":"8762_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"8762_CR2","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1200\/JCO.2009.27.4324","volume":"29","author":"PA Northcott","year":"2011","unstructured":"Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29(11):1408\u201314.","journal-title":"J Clin Oncol"},{"issue":"8","key":"8762_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1200\/JCO.2009.23.5952","volume":"28","author":"U Tabori","year":"2010","unstructured":"Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol. 2010;28(8):1345\u201350.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8762_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ccell.2014.11.002","volume":"27","author":"RM Hill","year":"2015","unstructured":"Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K, et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell. 2015;27(1):72\u201384.","journal-title":"Cancer Cell"},{"issue":"23","key":"8762_CR5","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1200\/JCO.2012.48.5052","volume":"31","author":"N Zhukova","year":"2013","unstructured":"Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013;31(23):2927\u201335.","journal-title":"J Clin Oncol"},{"issue":"6","key":"8762_CR6","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-016-1569-6","volume":"131","author":"V Ramaswamy","year":"2016","unstructured":"Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016;131(6):821\u201331.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"8762_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","volume":"31","author":"FMG Cavalli","year":"2017","unstructured":"Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell. 2017;31(6):737\u201354 e6.","journal-title":"Cancer Cell"},{"issue":"5","key":"8762_CR8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/cas.12925","volume":"107","author":"GH Huang","year":"2016","unstructured":"Huang GH, Xu QF, Cui YH, Li N, Bian XW, Lv SQ. Medulloblastoma stem cells: promising targets in medulloblastoma therapy. Cancer Sci. 2016;107(5):583\u20139.","journal-title":"Cancer Sci"},{"issue":"29","key":"8762_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj9138","volume":"8","author":"M Swiderska-Syn","year":"2022","unstructured":"Swiderska-Syn M, Mir-Pedrol J, Oles A, Schleuger O, Salvador AD, Greiner SM, et al. Noncanonical activation of GLI signaling in SOX2(+) cells drives medulloblastoma relapse. Sci Adv. 2022;8(29):eabj9138.","journal-title":"Sci Adv"},{"key":"8762_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.621093","volume":"11","author":"Y Sun","year":"2020","unstructured":"Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials. Front Pharm. 2020;11:621093.","journal-title":"Front Pharm"},{"issue":"246","key":"8762_CR11","doi-asserted-by":"publisher","first-page":"re6","DOI":"10.1126\/scisignal.2002906","volume":"5","author":"DJ Robbins","year":"2012","unstructured":"Robbins DJ, Fei DL, Riobo NA. The Hedgehog signal transduction network. Sci Signal. 2012;5(246):re6.","journal-title":"Sci Signal"},{"issue":"11","key":"8762_CR12","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nchembio.453","volume":"6","author":"CA Thorne","year":"2010","unstructured":"Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol. 2010;6(11):829\u201336.","journal-title":"Nat Chem Biol"},{"issue":"17","key":"8762_CR13","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1158\/0008-5472.CAN-14-0317","volume":"74","author":"B Li","year":"2014","unstructured":"Li B, Fei DL, Flaveny CA, Dahmane N, Baubet V, Wang Z, et al. Pyrvinium attenuates Hedgehog signaling downstream of smoothened. Cancer Res. 2014;74(17):4811\u201321.","journal-title":"Cancer Res"},{"issue":"4","key":"8762_CR14","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1158\/1078-0432.CCR-18-1319","volume":"25","author":"J Rodriguez-Blanco","year":"2019","unstructured":"Rodriguez-Blanco J, Li B, Long J, Shen C, Yang F, Orton D, et al. A CK1alpha activator penetrates the brain and shows efficacy against drug-resistant metastatic medulloblastoma. Clin Cancer Res. 2019;25(4):1379\u201388.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"8762_CR15","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.3390\/ijms21165940","volume":"21","author":"C Shen","year":"2020","unstructured":"Shen C, Nayak A, Melendez RA, Wynn DT, Jackson J, Lee E, et al. Casein kinase 1alpha as a regulator of Wnt-driven cancer. Int J Mol Sci. 2020;21(16):5940.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"8762_CR16","doi-asserted-by":"publisher","first-page":"e101969","DOI":"10.1371\/journal.pone.0101969","volume":"9","author":"B Li","year":"2014","unstructured":"Li B, Flaveny CA, Giambelli C, Fei DL, Han L, Hang BI, et al. Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis. PLoS ONE. 2014;9(7):e101969.","journal-title":"PLoS ONE"},{"issue":"485","key":"8762_CR17","doi-asserted-by":"publisher","first-page":"eaak9916","DOI":"10.1126\/scisignal.aak9916","volume":"10","author":"B Li","year":"2017","unstructured":"Li B, Orton D, Neitzel LR, Astudillo L, Shen C, Long J, et al. Differential abundance of CK1alpha provides selectivity for pharmacological CK1alpha activators to target WNT-dependent tumors. Sci Signal. 2017;10(485):eaak9916.","journal-title":"Sci Signal"},{"issue":"45","key":"8762_CR18","doi-asserted-by":"publisher","first-page":"6306","DOI":"10.1038\/onc.2017.232","volume":"36","author":"J Rodriguez-Blanco","year":"2017","unstructured":"Rodriguez-Blanco J, Pednekar L, Penas C, Li B, Martin V, Long J, et al. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma. Oncogene. 2017;36(45):6306\u201314.","journal-title":"Oncogene"},{"key":"8762_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108673","volume":"260","author":"K Peterson","year":"2024","unstructured":"Peterson K, Turos-Cabal M, Salvador AD, Palomo-Caturla I, Howell AJ, Vieira ME, et al. Mechanistic insights into medulloblastoma relapse. Pharm Ther. 2024;260:108673.","journal-title":"Pharm Ther"},{"issue":"2","key":"8762_CR20","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.18632\/oncotarget.6261","volume":"7","author":"CH Lee","year":"2016","unstructured":"Lee CH, Yu CC, Wang BY, Chang WW. Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs. Oncotarget. 2016;7(2):1215\u201326.","journal-title":"Oncotarget"},{"key":"8762_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev-biochem-060308-103103","volume":"79","author":"MR Fabian","year":"2010","unstructured":"Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351\u201379.","journal-title":"Annu Rev Biochem"},{"issue":"7","key":"8762_CR22","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.4161\/cc.19618","volume":"11","author":"YH Cha","year":"2012","unstructured":"Cha YH, Kim NH, Park C, Lee I, Kim HS, Yook JI. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle. 2012;11(7):1273\u201381.","journal-title":"Cell Cycle"},{"issue":"11","key":"8762_CR23","doi-asserted-by":"publisher","first-page":"a007906","DOI":"10.1101\/cshperspect.a007906","volume":"4","author":"KM Cadigan","year":"2012","unstructured":"Cadigan KM, Waterman ML. TCF\/LEFs and Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol. 2012;4(11):a007906.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"8762_CR24","first-page":"669","volume":"43","author":"N Fox","year":"1983","unstructured":"Fox N, Damjanov I, Knowles BB, Solter D. Immunohistochemical localization of the mouse stage-specific embryonic antigen 1 in human tissues and tumors. Cancer Res. 1983;43(2):669\u201378.","journal-title":"Cancer Res"},{"issue":"2","key":"8762_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccr.2008.12.016","volume":"15","author":"TA Read","year":"2009","unstructured":"Read TA, Fogarty MP, Markant SL, McLendon RE, Wei Z, Ellison DW, et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell. 2009;15(2):135\u201347.","journal-title":"Cancer Cell"},{"issue":"11","key":"8762_CR26","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1158\/0008-5472.CAN-09-0342","volume":"69","author":"RJ Ward","year":"2009","unstructured":"Ward RJ, Lee L, Graham K, Satkunendran T, Yoshikawa K, Ling E, et al. Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Res. 2009;69(11):4682\u201390.","journal-title":"Cancer Res"},{"issue":"4","key":"8762_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1593\/neo.91972","volume":"12","author":"RK Gandhirajan","year":"2010","unstructured":"Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, Schlosser A, et al. Small molecule inhibitors of Wnt\/beta-catenin\/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia. 2010;12(4):326\u201335.","journal-title":"Neoplasia"},{"issue":"1","key":"8762_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ccr.2014.05.005","volume":"26","author":"RJ Vanner","year":"2014","unstructured":"Vanner RJ, Remke M, Gallo M, Selvadurai HJ, Coutinho F, Lee L, et al. Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. Cancer Cell. 2014;26(1):33\u201347.","journal-title":"Cancer Cell"},{"issue":"12","key":"8762_CR29","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.3390\/biomedicines10123249","volume":"10","author":"CW Schultz","year":"2022","unstructured":"Schultz CW, Nevler A. Pyrvinium pamoate: past, present, and future as an anti-cancer drug. Biomedicines. 2022;10(12):3249.","journal-title":"Biomedicines"},{"issue":"7","key":"8762_CR30","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nm.3613","volume":"20","author":"Y Tang","year":"2014","unstructured":"Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P, et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 2014;20(7):732\u201340.","journal-title":"Nat Med"},{"issue":"51","key":"8762_CR31","doi-asserted-by":"publisher","first-page":"35494","DOI":"10.1074\/jbc.M114.595348","volume":"289","author":"J Long","year":"2014","unstructured":"Long J, Li B, Rodriguez-Blanco J, Pastori C, Volmar CH, Wahlestedt C, et al. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. J Biol Chem. 2014;289(51):35494\u2013502.","journal-title":"J Biol Chem"},{"issue":"12","key":"8762_CR32","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41416-020-01079-x","volume":"123","author":"MM Mita","year":"2020","unstructured":"Mita MM, Mita AC. Bromodomain inhibitors a decade later: a promise unfulfilled?. Br J Cancer. 2020;123(12):1713\u20134.","journal-title":"Br J Cancer"},{"issue":"9","key":"8762_CR33","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41573-021-00199-0","volume":"20","author":"MJ Henley","year":"2021","unstructured":"Henley MJ, Koehler AN. Advances in targeting \u2018undruggable\u2019 transcription factors with small molecules. Nat Rev Drug Discov. 2021;20(9):669\u201388.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"8762_CR34","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3892\/ijo.2016.3337","volume":"48","author":"L Xu","year":"2016","unstructured":"Xu L, Zhang L, Hu C, Liang S, Fei X, Yan N, et al. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells. Int J Oncol. 2016;48(3):1175\u201386.","journal-title":"Int J Oncol"},{"issue":"23","key":"8762_CR35","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1158\/1078-0432.CCR-14-3147","volume":"21","author":"C Venugopal","year":"2015","unstructured":"Venugopal C, Hallett R, Vora P, Manoranjan B, Mahendram S, Qazi MA, et al. Pyrvinium targets CD133 in human glioblastoma brain tumor-initiating cells. Clin Cancer Res. 2015;21(23):5324\u201337.","journal-title":"Clin Cancer Res"},{"issue":"7015","key":"8762_CR36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","volume":"432","author":"SK Singh","year":"2004","unstructured":"Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396\u2013401.","journal-title":"Nature"},{"issue":"4","key":"8762_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1042\/EBC20220016","volume":"66","author":"M Katoh","year":"2022","unstructured":"Katoh M, Katoh M. WNT signaling and cancer stemness. Essays Biochem. 2022;66(4):319\u201331.","journal-title":"Essays Biochem"},{"issue":"1","key":"8762_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ydbio.2005.09.051","volume":"292","author":"H Koso","year":"2006","unstructured":"Koso H, Ouchi Y, Tabata Y, Aoki Y, Satoh S, Arai K, et al. SSEA-1 marks regionally restricted immature subpopulations of embryonic retinal progenitor cells that are regulated by the Wnt signaling pathway. Dev Biol. 2006;292(1):265\u201376.","journal-title":"Dev Biol"},{"issue":"2","key":"8762_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01472-3","volume":"38","author":"W Zheng","year":"2021","unstructured":"Zheng W, Hu J, Lv Y, Bai B, Shan L, Chen K, et al. Pyrvinium pamoate inhibits cell proliferation through ROS-mediated AKT-dependent signaling pathway in colorectal cancer. Med Oncol. 2021;38(2):21.","journal-title":"Med Oncol"},{"issue":"5","key":"8762_CR40","first-page":"1602","volume":"5","author":"P Xia","year":"2015","unstructured":"Xia P, Xu XY. PI3K\/Akt\/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res. 2015;5(5):1602\u20139.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"8762_CR41","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1101\/gad.1627008","volume":"22","author":"D Hambardzumyan","year":"2008","unstructured":"Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008;22(4):436\u201348.","journal-title":"Genes Dev"},{"key":"8762_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113960","volume":"177","author":"J Feng","year":"2020","unstructured":"Feng J, Jiang W, Liu Y, Huang W, Hu K, Li K, et al. Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer. Biochem Pharm. 2020;177:113960.","journal-title":"Biochem Pharm"},{"issue":"1","key":"8762_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.canlet.2011.12.034","volume":"319","author":"Y Harada","year":"2012","unstructured":"Harada Y, Ishii I, Hatake K, Kasahara T. Pyrvinium pamoate inhibits proliferation of myeloma\/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. Cancer Lett. 2012;319(1):83\u20138.","journal-title":"Cancer Lett"},{"issue":"1","key":"8762_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","volume":"43","author":"Y Hu","year":"2024","unstructured":"Hu Y, Dong Z, Liu K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J Exp Clin Cancer Res. 2024;43(1):23.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"8762_CR45","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/onc.2016.235","volume":"36","author":"N Garg","year":"2017","unstructured":"Garg N, Bakhshinyan D, Venugopal C, Mahendram S, Rosa DA, Vijayakumar T, et al. CD133(+) brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence. Oncogene. 2017;36(5):606\u201317.","journal-title":"Oncogene"},{"issue":"12","key":"8762_CR46","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/biomedicines9121869","volume":"9","author":"YH Fu","year":"2021","unstructured":"Fu YH, Tseng CY, Lu JW, Lu WH, Lan PQ, Chen CY, et al. Deciphering the role of pyrvinium pamoate in the generation of integrated stress response and modulation of mitochondrial function in myeloid leukemia cells through transcriptome analysis. Biomedicines. 2021;9(12):1869.","journal-title":"Biomedicines"},{"key":"8762_CR47","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fonc.2012.00137","volume":"2","author":"I Ishii","year":"2012","unstructured":"Ishii I, Harada Y, Kasahara T. Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration. Front Oncol. 2012;2:137.","journal-title":"Front Oncol"},{"issue":"11","key":"8762_CR48","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1158\/1535-7163.MCT-20-0652","volume":"20","author":"CW Schultz","year":"2021","unstructured":"Schultz CW, McCarthy GA, Nerwal T, Nevler A, DuHadaway JB, McCoy MD, et al. The FDA-approved anthelmintic pyrvinium pamoate inhibits pancreatic cancer cells in nutrient-depleted conditions by targeting the mitochondria. Mol Cancer Ther. 2021;20(11):2166\u201376.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"8762_CR49","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/bjc.2016.152","volume":"114","author":"P Sancho","year":"2016","unstructured":"Sancho P, Barneda D, Heeschen C. Hallmarks of cancer stem cell metabolism. Br J Cancer. 2016;114(12):1305\u201312.","journal-title":"Br J Cancer"},{"issue":"7","key":"8762_CR50","doi-asserted-by":"publisher","first-page":"e177724","DOI":"10.1172\/JCI177724","volume":"135","author":"J Yang","year":"2025","unstructured":"Yang J, Lim JT, Santiago Raj PV, Corona MG, Chen C, Khawaja H, et al. Integrative analysis reveals therapeutic potential of pyrvinium pamoate in Merkel cell carcinoma. J Clin Invest. 2025;135(7):e177724.","journal-title":"J Clin Invest"},{"issue":"10","key":"8762_CR51","doi-asserted-by":"publisher","first-page":"e073839","DOI":"10.1136\/bmjopen-2023-073839","volume":"13","author":"FM Ponzini","year":"2023","unstructured":"Ponzini FM, Schultz CW, Leiby BE, Cannaday S, Yeo T, Posey J, et al. Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma. BMJ Open. 2023;13(10):e073839.","journal-title":"BMJ Open"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08762-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08762-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08762-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T02:02:00Z","timestamp":1780884120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08762-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8762"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08762-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DLF is a full-time employee at StemSynergy Therapeutics Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No human subjects were involved in this study. All animal experiments were conducted in compliance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals. Experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committees (IACUC) at the Medical University of South Carolina (IACUC-2019-00870-1) and the University of Miami (13-217). This Section is duplicated.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}}],"article-number":"545"}}